此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (AMBITION 1)

2026年11月6日 更新者:Novo Nordisk A/S

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

This study is being done to look at how well zenagamtide lowers blood sugar levels and body weight in people with type 2 diabetes when compared to placebo. Participants will either get zenagamtide, the treatment being tested or placebo, a treatment that has no active medicine in it. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.

研究概览

地位

尚未招聘

条件

研究类型

介入性

注册 (估计的)

200

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、404199
        • Chongqing University Three Gorges Hospital-Endocrinology
    • Jiangsu
      • Nanjing、Jiangsu、中国、210011
        • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
      • Zhenjiang、Jiangsu、中国、212001
        • The Affiliated Hospital of Jiangsu University-Endocrinology
    • Shandong
      • Jinan、Shandong、中国、250013
        • Jinan Central Hospital-General Medicine
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300134
        • Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Metabolism
      • Adapazarı/Sakarya、土耳其(türkiye)、54100
        • Sakarya Eğitim ve Araştırma Hastanesi- Dahiliye
      • Ankara、土耳其(türkiye)、06800
        • Ankara Bilkent Şehir Hastanesi-Dahiliye
      • Bursa、土耳其(türkiye)、16250
        • Bursa Şehir Hastanesi- Dahiliye
      • Giresun、土耳其(türkiye)、28100
        • Giresun Eğitim ve Araştırma Hastanesi-Dahiliye
      • Istanbul、土耳其(türkiye)、34722
        • Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Aile Hekimliği
      • Yuregir/Adana、土耳其(türkiye)、01060
        • Adana Şehir Eğitim ve Araştırma Hastanesi-Dahiliye
      • Bratislava、斯洛伐克、84108
        • KARDIO-SANUS, spol. s r.o.
      • Bytča、斯洛伐克、014 01
        • Diab - Int, s.r.o.
      • Košice、斯洛伐克、040 01
        • Univerzitna nemocnica L. Pasteura Kosice
      • Nové Zámky、斯洛伐克、940 59
        • FUNKYSTUFF s.r.o
      • Trnava、斯洛伐克、91701
        • JAL s.r.o.
      • Šurany、斯洛伐克、942 01
        • DEImedi, s. r. o.
      • Chiba-shi, Chiba、日本、260-0804
        • Akaicho Clinic_Internal medicine
      • Tokyo、日本、103-0027
        • Tokyo-Eki Center-building Clinic_Internal Medicine
      • Tokyo、日本、104-0031
        • Fukuwa Clinic_Internal Medicine
      • Tokyo、日本、160-0008
        • ToCROM Clinic_Internal Medicine
    • Osaka
      • Suita-shi、Osaka、日本、565-0853
        • OCROM Clinic_Internal medicine
      • Katowice、波兰、40-648
        • Pro Familia Altera Sp. z o.o.
      • Malbork、波兰、82-200
        • Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o.
      • Oświęcim、波兰、32-600
        • Formed 2 Sp. z o.o.
      • Staszów、波兰、28-200
        • Velocity Nova Sp. z o.o.
      • Warsaw、波兰、00-710
        • NBR Polska Tomasz Klodawski
      • Świnoujście、波兰、72-600
        • Balticmed Świnoujście Sp. z o. o.
    • Masovian Voivodeship
      • Płock、Masovian Voivodeship、波兰、09-407
        • Cbk Med Clinic Sp. z o.o.
      • San Juan、波多黎各、00907
        • Solace Clinical Research
      • Bucharest、罗马尼亚、013764
        • SC Nutrilife SRL
      • Bucharest、罗马尼亚、050159
        • Institutul De Pneumoftiziologie Marius Nasta
      • Sibiu、罗马尼亚、550371
        • SC Gensan SRL, Policlinica ASTRA
    • Bihor County
      • Oradea、Bihor County、罗马尼亚、410147
        • Diabdana S.R.L.
    • Mureș County
      • Reghin、Mureș County、罗马尼亚、545300
        • Poli Cardinal Med Srl
      • Târgu Mureş、Mureș County、罗马尼亚、540142
        • Sc Mediab Srl
    • California
      • Fountain Valley、California、美国、92708
        • Ark Clinical Research
      • Los Angeles、California、美国、90015
        • Los Angeles Institute for Metabolic Research
      • Spring Valley、California、美国、91978
        • Encompass Clinical Research_Spring Valley
    • Florida
      • Hollywood、Florida、美国、33024
        • Encore Medical Research LLC
      • Miami、Florida、美国、33155
        • My Preferred Research
      • Orlando、Florida、美国、32825
        • Florida Institute for Clinical research
      • Weston、Florida、美国、33331
        • Encore Medical Research of Weston
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Brigham & Women's Hospital
    • North Carolina
      • Wilmington、North Carolina、美国、28401
        • Accellacare
    • Pennsylvania
      • Washington、Pennsylvania、美国、15301
        • Preferred Primary Care physicians Washington
    • Texas
      • Houston、Texas、美国、77081
        • Southwest Clinical Trials
      • San Antonio、Texas、美国、78222
        • Pinnacle Clinical Research

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria:

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 30 days before screening.
  • Treatment naïve to any glucose-lowering medication(s).

Exclusion criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
  • Current treatment or history of treatment with any medication for the indication of diabetes, or treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues for any indication. However, previous insulin treatment during Gestational Diabetes Mellitus is allowed.
  • Treatment with any medication for the indication of obesity before screening.
  • Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening.
  • Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening.
  • Planned coronary, carotid or peripheral artery revascularisation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Participants will receive placebo matched to zenagamtide subcutaneously.

Placebo matched to zenagamtide will be administered subcutaneously once weekly.

实验性的:Zenagamtide

Participants will receive zenagamtide subcutaneously.

Zenagamtide will be administered subcutaneously once weekly.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in glycated haemoglobin (HbA1c)
大体时间:From baseline (week 0) to week 44

Measured as percentage (%) - points.

From baseline (week 0) to week 44

次要结果测量

结果测量
措施说明
大体时间
Relative change in body weight
大体时间:From baseline (week 0) to week 44

Measured as %.

From baseline (week 0) to week 44
Change in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
大体时间:From baseline (week 0) to week 44

Measured as ratio to baseline.

From baseline (week 0) to week 44
Change in triglycerides
大体时间:From baseline (week 0) to week 44

Measured as ratio to baseline.

From baseline (week 0) to week 44
Change in non-high-density lipoprotein (non-HDL) cholesterol
大体时间:From baseline (week 0) to week 44

Measured as ratio to baseline.

From baseline (week 0) to week 44
Change in high sensitivity C-reactive protein (hsCRP)
大体时间:From baseline (week 0) to week 44

Measured as ratio to baseline.

From baseline (week 0) to week 44
Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals)
大体时间:From baseline (week 0) to week 44

Measured as millimoles per liter (mmol/L).

From baseline (week 0) to week 44
Change in systolic blood pressure
大体时间:From baseline (week 0) to week 44

Measured as millimeters of mercury (mmHg).

From baseline (week 0) to week 44

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Transparency (dept. 2834)、Novo Nordisk A/S

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月10日

初级完成 (估计的)

2028年6月5日

研究完成 (估计的)

2028年8月28日

研究注册日期

首次提交

2026年11月6日

首先提交符合 QC 标准的

2026年11月6日

首次发布 (实际的)

2026年11月12日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • NN9489-8033
  • U1111-1335-3191 (其他标识符:World Health Organization (WHO))
  • 2026-525470-18 (其他标识符:European Medical Agency (EMA))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅